Literature DB >> 5541137

The pharmacokinetics of daunomycin in man.

D S Alberts, N R Bachur, J L Holtzman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5541137     DOI： 10.1002/cpt197112196

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  25 in total

Review 1.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 2.  A modern view of pharmacokinetics.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1973-10

Review 3.  Antineoplastic and immunosuppressive drugs. I. Biochemical and clinical pharmacological considerations.

Authors:  A H Chalmers; L A Burgoyne; A W Murray
Journal:  Drugs       Date:  1972       Impact factor: 9.546

Review 4.  Liposomes. Opportunities in drug delivery.

Authors:  T M Allen
Journal:  Drugs       Date:  1997       Impact factor: 9.546

5.  Therapy of acute myelocytic leukemia. Daunomycin contrasted with a combination of cytosine arabinoside and 6-thioguanine.

Authors:  J L Poth; P K Johnson; R P George; S L Schrier
Journal:  Calif Med       Date:  1972-12

Review 6.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

7.  Inactivation of anthracyclines by serum heme proteins.

Authors:  Brett A Wagner; Lynn M Teesch; Garry R Buettner; Bradley E Britigan; C Patrick Burns; Krzysztof J Reszka
Journal:  Chem Res Toxicol       Date:  2007-05-12       Impact factor: 3.739

8.  Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages.

Authors:  Y N Hui; H C Liang; Y S Cai; B Kirchhof; K Heimann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-02       Impact factor: 3.117

9.  Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.

Authors:  Federico Pea; Domenico Russo; Mariagrazia Michieli; Daniela Damiani; Renato Fanin; Angela Michelutti; Teresa Michelutti; Stefano Piccolrovazzi; Michele Baccarani; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.

Authors:  S O Nilsson; B Andersson; S Eksborg; M Beran; H Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.